|
Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program. |
| |
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merrimack; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merrimack; novartis |
Speakers' Bureau - amgen; Bayer; Celgene; roche; sanofi |
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst) |
Other Relationship - Celgene; emd serono; Halozyme; Roche; sanofi |
| |
|
Speakers' Bureau - Taiho Pharmaceutical |
| |
|
Consulting or Advisory Role - BTG; Merrimack |
Research Funding - AVEO; Boston Biomedical; Bristol-Myers Squibb; Cleave Biosciences; Genentech; Novartis; Taiho Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Taiho Pharmaceutical |